Nephrotic Syndrome (NS)/Focal Segmental Glomerulosclerosis (FSGS) Panel
Use
This test is designed for individuals with relevant features who have a clinical or suspected diagnosis of nephrotic syndrome or focal segmental glomerulosclerosis. It is also suitable for those with steroid-resistant nephrotic syndrome, individuals with early-onset chronic kidney disease before age 25, and those with a family history of presumed nephrotic syndrome or focal segmental glomerulosclerosis without previous genetic testing.
Special Instructions
The panel analyzes 72 genes using NGS with CNV capabilities on either an Exome or Genome platform. It is specifically tailored to detect mutations associated with nephrotic syndrome and focal segmental glomerulosclerosis.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration, and the performance characteristics were validated following CAP and CLIA regulations. Results may not cover all potential genetic causes due to the limitations inherent in the current understanding of genetic contributions to nephrotic syndrome and focal segmental glomerulosclerosis.
New York Approved
Methodology
NGS
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided